甲状腺疾病治疗市场 - 按药物类型（左旋甲状腺素、碘塞罗宁、咪唑类化合物、β-阻断剂）、疾病（甲状腺功能减退症、甲状腺功能亢进）、给药途径、配销通路- 全球预测（2024 - 2032）

由于全球甲状腺疾病（包括甲状腺功能减退症、甲状腺功能亢进症和甲状腺癌）盛行率不断上升，预计 2024 年至 2032 年甲状腺疾病治疗市场规模的复合年增长率将达到 3.9%。根据《柳叶刀》报道，甲状腺疾病影响全球约 2 亿人。碘缺乏、自体免疫疾病、遗传倾向和生活方式改变等因素导致甲状腺疾病的高发生率，尤其是在老年族群。随着甲状腺健康意识的增强和诊断能力的提高，越来越多的人寻求医疗协助。

医疗技术和治疗的进步正在推动甲状腺疾病治疗的创新。标靶治疗、放射性碘治疗、微创手术技术、精准医疗等新的治疗手段正在为患者提供更合适、更有效的治疗。新诊断工具和生物标记的发展也使得甲状腺疾病的早期诊断和监测成为可能，同时促进及时介入和改善患者的治疗结果。

甲状腺疾病治疗产业分为药物类型、疾病、给药途径、配销通路和区域。

根据药物类型，预计到 2032 年，β 受体阻断剂领域的市场规模将出现大幅复合年增长率，因为它能有效控制与甲状腺功能亢进相关的症状。 β-受体阻断剂，如普萘洛尔和阿替洛尔，透过阻断过量甲状腺激素对心血管系统的影响，有助于缓解心悸、颤抖和焦虑等症状。当透过药物、放射性碘治疗或手术解决甲状腺功能亢进的根本原因时，这些药物还可以缓解症状。

由于甲状腺机能亢进疾病在全球的盛行率不断增加，预计 2024 年至 2032 年期间，甲状腺疾病治疗产业将显着成长。甲状腺功能亢进以甲状腺过度活跃为特征，可引起心跳加速、体重减轻和焦虑等症状，同时严重影响患者的生活品质。甲状腺功能亢进的医疗干预措施，包括药物、放射性碘治疗和手术，对于控制症状、使甲状腺激素水平正常化和预防併发症也变得越来越必要。

由于医疗基础设施的快速扩张和医疗服务的普及，预计到 2032 年，亚太地区甲状腺疾病治疗产业将以可观的速度成长。由于缺碘、生活方式的改变和意识的提高，该地区甲状腺疾病的盛行率很高，导致对甲状腺功能减退症治疗的高需求，刺激了该地区市场的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 甲状腺疾病盛行率增加
    • 药物製剂技术进步
    • 增加医疗保健支出
  • 产业陷阱与挑战
    • 治疗的副作用和併发症
    • 严格的监管场景
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按药物类型，2021 - 2032

• 主要趋势
• 左旋甲状腺素
• 碘塞罗宁
• 丙基硫氧嘧啶
• 咪唑类化合物
• β-受体阻断剂
• 其他药物种类

第 6 章：市场估计与预测：按疾病分类，2021 - 2032 年

• 主要趋势
• 甲状腺功能低下症
• 甲状腺功能亢进症

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 静脉
• 其他给药途径

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 批发商/分销商
• 零售连锁店
• 网上发行
• 其他分销管道

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Abbott Laboratories
• AbbVie Inc.
• Aspen Pharmacare Holdings Limited
• Glenmark Pharmaceuticals Ltd.
• Lannett Company, Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited

Thyroid gland disorder treatment market size is expected to register 3.9% CAGR between 2024 to 2032, driven by the increasing prevalence of thyroid disorders worldwide including hypothyroidism, hyperthyroidism, and thyroid cancer. As per Lancet, thyroid diseases impact approximately 200 million individuals globally. Factors, such as iodine deficiency, autoimmune diseases, genetic predisposition, and lifestyle changes are contributing to the high incidence of thyroid diseases especially in the elderly population. With the increasing thyroid health awareness and improving diagnostic capabilities, more individuals are seeking medical help.

Advancements in medical technology and treatment are driving innovations in the management of thyroid diseases. New therapeutic approaches, including targeted therapy, radioiodine therapy, minimally invasive surgical techniques, and precision medicine are providing more appropriate and effective treatment for patients. The development of new diagnostic tools and biomarkers is also enabling the earlier diagnosis and monitoring of thyroid disease while facilitating timely intervention and improving patient outcomes.

The thyroid gland disorder treatment industry is divided into drug type, disease, route of administration, distribution channel, and region.

Based on drug type, the market size from the beta blocker segment is projected to observe substantial CAGR through 2032 as it is effective in managing the symptoms associated with hyperthyroidism. Beta-blockers, such as propranolol and atenolol help in relieving symptoms like heart palpitations, tremors, and anxiety by blocking the effects of excess thyroid hormone on the cardiovascular system. These drugs also provide symptom relief, when the root cause of hyperthyroidism is addressed, either through medication, radioactive iodine therapy, or surgery.

Thyroid gland disorder treatment industry from the hyperthyroidism disease segment is anticipated to record significant growth rate during 2024- 2032 due to the increasing prevalence of this condition worldwide. Hyperthyroidism, characterized by overactive thyroid glands, can cause symptoms including rapid heartbeat, weight loss and anxiety, while significantly affecting the quality of life of patients. Medical interventions for hyperthyroidism, including medication, radioactive iodine therapy and surgery, have also grown necessary to manage symptoms, normalize thyroid hormone levels and prevent complications.

Asia Pacific thyroid gland disorder treatment industry is predicted to grow at a decent rate through 2032, attributed to the rapidly expanding healthcare infrastructure and the increasing access to medical services. The strong prevalence of thyroid disease in the region due iodine deficiency, changing lifestyles and increasing awareness is contributing to the high demand for treatment of hypothyroidism, stimulating the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of thyroid disorders
    • 3.2.1.2 Technological advancements in drug formulations
    • 3.2.1.3 Increasing healthcare expenditure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and complications of treatment
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Levothyroxine
• 5.3 Liothyronine
• 5.4 Propylthiouracil
• 5.5 Imidazole-based compounds
• 5.6 Beta-blockers
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypothyroidism
• 6.3 Hyperthyroidism

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Intravenous
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Wholesalers/distributors
• 8.3 Retail chain
• 8.4 Online distribution
• 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AbbVie Inc.
• 10.3 Aspen Pharmacare Holdings Limited
• 10.4 Glenmark Pharmaceuticals Ltd.
• 10.5 Lannett Company, Inc.
• 10.6 Merck & Co., Inc.
• 10.7 Mylan N.V.
• 10.8 Novartis AG
• 10.9 Pfizer Inc.
• 10.10 Sun Pharmaceutical Industries Limited